Answers are grounded in this paper and cite their sources.
Cross-sectional study identifies prevalent ESBL bacteria in pregnant women, suggesting targeted antibiotic therapy is needed.
Background. Extended-spectrum β -lactamase (ESBL)-producing bacteria pose a global challenge because of resistance developing against a wide range of antimicrobial agents, complicating available treatment options. Thus, identifying the prevalent bacterial species producing ESBL enzymes and understanding how they are susceptible to antibiotics is necessary to inform effective treatment guidelines. Objective. We sought to characterize ESBL-producing bacteria isolated from pregnant women’s urine at Itojo Hospital, Ntungamo district, Southwestern Uganda. Methods. We conducted a cross-sectional study where we collected and analysed 340 urine samples from 340 pregnant women. We did antimicrobial susceptibility testing using the Kirby–Bauer disc diffusion method. Isolates were screened for ESBL production and confirmed using the combination disc test. Genotypic characterization was confirmed using multiplex PCR to detect bla TEM, bla CTX-M and bla SHV genes. Results. The prevalence of ESBL-producing bacteria was 29.7% (101/340). Escherichia coli 36/101 (35.6%) and Klebsiella species 33/101 (32.7%) were predominant ESBL producers. Genotypic analysis revealed bla TEM 50/101 (49.5%) and bla CTX-M 31/101 (30.7%) as the most prevalent genes, while bla SHV was less common, 8/101 (7.9%) Conclusion. The high prevalence of ESBL-producing bacteria and their resistance to commonly used antibiotics highlighted the need for targeted antibiotic therapy, antimicrobial stewardship and regular molecular surveillance.
No takes yet. Share an insight, caveat, or question.
Twinomujuni et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: